GNTA
NASDAQGenenta Science S.p.A.
Price$1.17+0.58 (+98.81%)
2026-05-212026-08-25
News · 26 weeks32-100%
2026-03-012026-08-23
Mix1090d
- SEC Filings8(80%)
- Other2(20%)
Latest news
25 items- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- PRGenenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic ArmMILAN and NAPLES, Italy, July 23, 2026 (GLOBE NEWSWIRE) -- Sòphia High Tech S.r.l. (Sòphia HT), an Italian aerospace and defense company manufacturing critical parts for Europe's space and defense programs, backed by Genenta Science S.p.A. (NASDAQ:GNTA) — evolving into Saentra Forge¹, a strategic industrial consolidator focused on aerospace, defense, biotech and Italian national-security-related technologies — today announced the unveiling of ROMAN, a robotic arm engineered to perform inspection and maintenance operations inside a nuclear fusion machine. Sòphia HT and its partners Department of Industrial Engineering (DII) and Herobots designed, developed, produced, assembled, tested and i
- PRGenenta-Backed Sòphia High Tech Reports Fiscal Year 2025 ResultsFiscal Year 2025 Highlights FY2025 sales rose 29.3% to €7.17 million; total value of production increased 34.7% to €8.47 millionEBITDA grew 68.1% to €1.61 million, expanding the EBITDA margin by approximately 380 basis points to 19.0%Operating profit advanced 80.8% to €1.21 million MILAN, July 22, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on aerospace, defense, biotech and Italian national-security-related technologies, today announced that the Board of Directors of Sòphia High Tech S.r.l. ("Sòphia HT") has approved the company’s financial statements for the fiscal year ended December 31, 2025.
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Paracchi Pierluigi4 - Genenta Science S.p.A. (0001838716) (Issuer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- PRGenenta signs Definitive Agreements with Sophia High TechMILAN,Italy, April 23, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it has signed definitive agreements2 with Sòphia High Tech S.r.l., (Sòphia HT) an Italian company manufacturing critical parts for Europe's space and defense programs. Genenta expects to fund a total of €6.0 million in two tranches. With the closing of the first tranche, Genenta will obtain a 19.9% stake, and with the closing of the second tranche, Genenta will own a 51% stake in Sòphia HT. The proceeds are expected to be deploy
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- INSIDERSEC Form 4 filed by Paracchi Giacomoantonio4 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 4 filed by Galimi Francesco4 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 4 filed by Mutti Miguel Maria4 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 4 filed by Sharei Armon4 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 4 filed by Slansky Richard B4 - Genenta Science S.p.A. (0001838716) (Issuer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- PRGenenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programsMILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it has entered into a binding offer with Sòphia High Tech S.r.l., (Sòphia HT) an Italian company manufacturing critical parts for Europe's space and defense programs, under which Genenta will fund Sòphia through two reserved capital increases, with the goal of reaching a controlling stake upon the achievement of defined performance milestones. The transaction with Sòphia High Tech would be completed in two phases and remains subject to
- INSIDERSEC Form 3 filed by new insider Paracchi Giacomoantonio3 - Genenta Science S.p.A. (0001838716) (Issuer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
GNTA FAQ
7 questionsWhat does Genenta Science S.p.A. do?
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in...Where does GNTA stock trade?
Genenta Science S.p.A. (GNTA) is listed on NASDAQ.What sector and industry is GNTA in?
Genenta Science S.p.A. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Genenta Science S.p.A. go public?
Genenta Science S.p.A. (GNTA) completed its IPO in 2021.What are analysts saying about GNTA?
Genenta Science S.p.A. has had 2 recent analyst actions on file. The most recent action was from ROTH MKM: Buy with a $1500.00 price target on 2023-06-29. Recent price targets range from $1500.00 to $2500.00.What companies are similar to GNTA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare GNTA side-by-side with any of them on Quantisnow.How can I track GNTA on Quantisnow?
Quantisnow aggregates Genenta Science S.p.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GNTA to receive live email and push alerts on every new disclosure.